<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Influenza Other Respir Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Influenza Other Respir Viruses</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1750-2659</journal-id><journal-id journal-id-type="publisher-id">IRV</journal-id><journal-title-group><journal-title>Influenza and Other Respiratory Viruses</journal-title></journal-title-group><issn pub-type="ppub">1750-2640</issn><issn pub-type="epub">1750-2659</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22712831</article-id><article-id pub-id-type="pmc">5779839</article-id><article-id pub-id-type="doi">10.1111/j.1750-2659.2012.00395.x</article-id><article-id pub-id-type="publisher-id">IRV395</article-id><article-categories><subj-group subj-group-type="heading"><subject>Part 1</subject><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></subj-group><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Virus detection and its association with symptoms during influenza&#x02010;like illness in a sample of healthy adults enrolled in a randomised controlled vaccine trial</article-title><alt-title alt-title-type="left-running-head">Howard <italic>et&#x000a0;al.</italic></alt-title><alt-title alt-title-type="right-running-head">Viruses associated with ILI in healthy adults</alt-title></title-group><contrib-group><contrib id="cr1" contrib-type="author"><name><surname>Howard</surname><given-names>Peter F.</given-names></name><xref ref-type="aff" rid="a1">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="fn1">
<sup>&#x02020;</sup>
</xref></contrib><contrib id="cr2" contrib-type="author"><name><surname>McCaw</surname><given-names>James M.</given-names></name><xref ref-type="aff" rid="a1">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="fn1">
<sup>&#x02020;</sup>
</xref></contrib><contrib id="cr3" contrib-type="author"><name><surname>Richmond</surname><given-names>Peter C.</given-names></name><xref ref-type="aff" rid="a2">
<sup>2</sup>
</xref></contrib><contrib id="cr4" contrib-type="author"><name><surname>Nissen</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="a3">
<sup>3</sup>
</xref></contrib><contrib id="cr5" contrib-type="author"><name><surname>Sloots</surname><given-names>Theo</given-names></name><xref ref-type="aff" rid="a3">
<sup>3</sup>
</xref></contrib><contrib id="cr6" contrib-type="author"><name><surname>Lambert</surname><given-names>Stephen B.</given-names></name><xref ref-type="aff" rid="a3">
<sup>3</sup>
</xref></contrib><contrib id="cr7" contrib-type="author"><name><surname>Lai</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="a4">
<sup>4</sup>
</xref></contrib><contrib id="cr8" contrib-type="author"><name><surname>Greenberg</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="a4">
<sup>4</sup>
</xref></contrib><contrib id="cr9" contrib-type="author"><name><surname>Nolan</surname><given-names>Terry</given-names></name><xref ref-type="aff" rid="a1">
<sup>1</sup>
</xref></contrib><contrib id="cr10" contrib-type="author"><name><surname>McVernon</surname><given-names>Jodie</given-names></name><xref ref-type="aff" rid="a1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="a1">
<label><sup>1</sup></label>Murdoch Children&#x02019;s Research Institute &#x00026; Melbourne School of Population Health, The University of Melbourne, Parkville, Vic., Australia</aff><aff id="a2">
<label><sup>2</sup></label>University of Western Australia, School of Paediatrics and Child Health &#x00026; Telethon Institute for Child Health Research, Princess Margaret Hospital for Children, Perth, WA, Australia</aff><aff id="a3">
<label><sup>3</sup></label>Queensland Paediatric Infectious Diseases Laboratory, Queensland Children&#x02019;s Medical Research Institute and Sir Albert Sakzewski Virus Research Centre, Queensland Children&#x02019;s Health Services, The University of Queensland, Brisbane, Qld, Australia</aff><aff id="a4">
<label><sup>4</sup></label>Clinical Research and Development, CSL Limited, Parkville, Vic., Australia.</aff><author-notes><corresp id="correspondenceTo">James McCaw, Vaccine and Immunisation Research Group, Melbourne School of Population Health and Murdoch Childrens Research Institute, The University of Melbourne, Parkville, Vic. 3010, Australia. E&#x02010;mail: <email>jamesm@unimelb.edu.au</email></corresp><fn id="fn1"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>19</day><month>6</month><year>2012</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2013</year></pub-date><volume>7</volume><issue>3</issue><issue-id pub-id-type="doi">10.1111/irv.2013.7.issue-3</issue-id><fpage>330</fpage><lpage>339</lpage><history>
Accepted 30 April 2012. Published online 19 June 2012.</history><permissions><copyright-statement content-type="article-copyright">&#x000a9; 2012 Blackwell Publishing Ltd</copyright-statement></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:IRV-7-330.pdf"/><abstract><p>
<bold>Background&#x02002;</bold> Viral respiratory infections are associated with significant morbidity and mortality. Many new aetiological agents have been described recently.</p><p>
<bold>Objectives&#x02002;</bold> We looked for respiratory viruses in a population&#x02010;based sample of healthy adults with influenza&#x02010;like illness (ILI). We investigated host and spatio&#x02010;temporal associations with virus isolation and host, spatio&#x02010;temporal and virus associations with self&#x02010;reported symptoms.</p><p>
<bold>Patients/Methods&#x02002;</bold> We recruited 586 participants experiencing 651 illness episodes from a population of healthy adults enrolled in an influenza vaccine effectiveness trial. At ILI assessment visits, a respiratory swab was collected and tested for viruses using a combination of polymerase chain reaction (PCR) assays. Participants also completed a questionnaire detailing their clinical course in 336 episodes.</p><p>
<bold>Results&#x02002;</bold> Of 643 samples analysed, a virus was identified in 44%. Half were picornaviruses, with influenza and coronaviruses the next most common. Individuals with influenza were significantly less likely to have been immunised than the reference (virus negative) population (OR&#x02003;=&#x02003;0&#x000b7;52 (0&#x000b7;31, 0&#x000b7;87) <italic>P&#x02003;</italic>=<italic>&#x02003;</italic>0&#x000b7;01).</p><p>The mean symptom score (95% CI) reported by individuals with influenza was significantly higher than in all other episodes [Influenza: 10&#x000b7;2 (9&#x000b7;4, 10&#x000b7;9); Other: 7&#x000b7;4 (7&#x000b7;2, 7&#x000b7;7); Difference (95% CI): 2&#x000b7;5 (1&#x000b7;5, 3&#x000b7;5); <italic>P&#x02003;</italic>&#x0003c;<italic>&#x02003;</italic>0&#x000b7;001]. In an analysis restricted to influenza&#x02010;positive cases, the symptom score was not attenuated by vaccination.</p><p>
<bold>Conclusions&#x02002;</bold> Our findings indicate that a greater number of symptoms are displayed by individuals presenting with influenza confirmed ILI compared with other agents that cause ILI. While influenza vaccination reduced the probability of influenza virus detection, symptom score for influenza&#x02010;positive ILI was not attenuated.</p></abstract><kwd-group><kwd id="k1">Epidemiology</kwd><kwd id="k2">human</kwd><kwd id="k3">influenza</kwd><kwd id="k4">influenza vaccines</kwd><kwd id="k5">picornavirus infection</kwd><kwd id="k6">respiratory tract infection</kwd></kwd-group><counts><fig-count count="2"/><table-count count="6"/><page-count count="10"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2013</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.6.9 mode:remove_FC converted:04.11.2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="ss1"><title>Introduction</title><p>Viral infections of the respiratory tract are responsible for significant morbidity and mortality worldwide.<xref rid="b1" ref-type="ref">
<sup>1</sup>
</xref> Influenza viruses, rhinoviruses (HRVs), adenoviruses, respiratory syncytial virus (RSV) and parainfluenza viruses (PIVs) are the most common aetiological agents in such infections.<xref rid="b2" ref-type="ref">
<sup>2</sup>
</xref>, <xref rid="b3" ref-type="ref">
<sup>3</sup>
</xref> Most of the burden of disease caused by these viruses occurs at the extremes of age, with hospitalisation rates among preschool&#x02010;aged children similar to those in the elderly.<xref rid="b4" ref-type="ref">
<sup>4</sup>
</xref> The annual estimated cost of influenza alone to the Australian healthcare system is $115&#x02003;million.<xref rid="b5" ref-type="ref">
<sup>5</sup>
</xref> Increased recognition of the burden of influenza morbidity and mortality has resulted in broadening of recommendations for influenza vaccination in the United States<xref rid="b6" ref-type="ref">
<sup>6</sup>
</xref> and Canada.<xref rid="b7" ref-type="ref">
<sup>7</sup>
</xref>, <xref rid="b8" ref-type="ref">
<sup>8</sup>
</xref>
</p><p>In recent decades, extensive studies have identified hitherto unknown agents that are aetiological in acute respiratory tract infections (ARIs). Associated developments in technologies for virus detection<xref rid="b9" ref-type="ref">
<sup>9</sup>
</xref> have facilitated their epidemiological characterisation. Despite these advances, it remains the case that no known respiratory virus can be identified in 30&#x02013;40% of all ARI episodes, suggesting that additional respiratory pathogens are likely to exist.<xref rid="b10" ref-type="ref">
<sup>10</sup>
</xref>, <xref rid="b11" ref-type="ref">
<sup>11</sup>
</xref> In support of this notion, a number of previously undescribed viruses have been identified by analysis of clinical specimens from the human respiratory tract since 2001: human metapneumovirus,<xref rid="b12" ref-type="ref">
<sup>12</sup>
</xref> SARS coronavirus,<xref rid="b13" ref-type="ref">
<sup>13</sup>
</xref> coronavirus NL63,<xref rid="b14" ref-type="ref">
<sup>14</sup>
</xref> coronavirus HKU1,<xref rid="b15" ref-type="ref">
<sup>15</sup>
</xref> human bocaviruses,<xref rid="b16" ref-type="ref">
<sup>16</sup>
</xref> novel rhinoviruses<xref rid="b3" ref-type="ref">
<sup>3</sup>
</xref> and the recently described KI and WU polyomaviruses.<xref rid="b17" ref-type="ref">
<sup>17</sup>
</xref>, <xref rid="b18" ref-type="ref">
<sup>18</sup>
</xref>
</p><p>Several of the authors have previously reported on the community epidemiology of viral acute respiratory infections in a cohort of children &#x0003c;5&#x02003;years of age.<xref rid="b19" ref-type="ref">
<sup>19</sup>
</xref> Within a large, industry&#x02010;sponsored vaccine trial, we conducted a study of the viral aetiology of respiratory tract infections experienced by healthy, community dwelling adults reporting symptoms of influenza&#x02010;like illness (ILI).</p></sec><sec id="ss2"><title>Methods</title><sec id="ss3"><title>Study population</title><p>A total of 7544 healthy, non&#x02010;pregnant adults aged from at least 18&#x02003;years to &#x0003c;65&#x02003;years were enrolled in a placebo&#x02010;controlled phase IV efficacy trial of a licensed seasonal trivalent influenza vaccine (Fluvax&#x000ae;, CSL Ltd, Parkville, Vic., Australia), conducted between March and November 2008 at 21 study sites in Australia and New Zealand (Clinicaltrials.gov, #NCT00562484). Main exclusion criteria were the following: allergy to any of the vaccine components; medically unstable clinical condition; planned or current pregnancy; lactation; history of Guillain&#x02013;Barr&#x000e9; Syndrome; confirmed or suspected immunosuppressive condition; current or recent immunosuppressive therapy; concurrent participation in a clinical trial or use of an investigational compound; or recommended for seasonal influenza vaccination according to guidelines in Australia<xref rid="b20" ref-type="ref">
<sup>20</sup>
</xref> or New Zealand.<xref rid="b21" ref-type="ref">
<sup>21</sup>
</xref> Following provision of written informed consent, participants were randomly assigned to receive vaccine or placebo in a 2:1 ratio.</p><p>They were reminded weekly to report symptoms of ILI, commencing 14&#x02003;days after vaccination and ending on the 30 November 2008. Participants meeting the ILI case definition of at least one respiratory symptom (cough, sore throat, runny nose or nasal congestion) and at least one systemic symptom (fever &#x02265;37&#x000b7;8&#x000b0;C, feverishness, chills or myalgia) were asked to present for collection of respiratory swabs for influenza detection.</p><p>Within the industry&#x02010;sponsored RCT, we nested a cohort for this study, involving a denominator population of 4868 participants from 12 Australian study centres (<xref rid="f1" ref-type="fig">Figure&#x000a0;1</xref>). All participants from these sites presenting for ILI assessment were invited to consent to participation in this &#x02018;virus substudy&#x02019;, which involved collection of one extra respiratory swab.</p><fig fig-type="Figure" xml:lang="en" id="f1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>&#x02002;Flow diagram for influenza&#x02010;like illness episode (by participant) inclusion in the substudy.</p></caption><graphic id="nlm-graphic-1" xlink:href="IRV-7-330-g001"/></fig><p>Both the primary phase IV efficacy trial and the substudy were ethically approved at each of the 12 participating substudy sites (as listed in the <xref rid="ss14" ref-type="ack">Acknowledgements</xref>). At some substudy sites, participants were reimbursed for time and inconvenience according to approved practices by their respective ethics committees.</p></sec><sec id="ss4"><title>Study procedures</title><p>At the ILI visit, a nose or throat specimen was collected using a COPAN<sup>&#x02122;</sup> dry flocked swab and initially transported to a local holding laboratory where it was frozen. Specimens were returned, together with those collected for the primary study, to CSL Ltd&#x02019;s laboratories (COPAN Diagnostics Inc., Murrieta, CA, USA) in Parkville and shipped on dry ice in several consignments to the Queensland Paediatric Infectious Diseases Laboratory. Samples were tested for viruses including: influenza A and B, RSV, parainfluenza viruses (1,2,3), adenoviruses, human metapneumovirus (hMPV)<xref rid="b22" ref-type="ref">
<sup>22</sup>
</xref> picornaviruses,<xref rid="b23" ref-type="ref">
<sup>23</sup>
</xref>, <xref rid="b24" ref-type="ref">
<sup>24</sup>
</xref> bocaviruses,<xref rid="b25" ref-type="ref">
<sup>25</sup>
</xref> coronaviruses (OC43, 229E, NL63 and HKU1)<xref rid="b26" ref-type="ref">
<sup>26</sup>
</xref>, <xref rid="b27" ref-type="ref">
<sup>27</sup>
</xref> and KI and WU polyomaviruses <xref rid="b28" ref-type="ref">
<sup>28</sup>
</xref> using a combination of multiplexed and uniplexed conventional and real&#x02010;time polymerase chain reaction (PCR) assays.</p><p>Participants were given a questionnaire requesting information about the clinical course of their illness including: symptoms experienced along with any complications, medical treatment sought, interruption to usual activities and duration of the episode. A reply paid envelope was provided within which to return the questionnaire to the Vaccine and Immunisation Research Group in Melbourne.</p></sec><sec id="ss5"><title>Outcome measures</title><p>The primary unit of analysis was the ILI episode, with potential for individuals to have repeated illness presentations over the course of the study. All events were assumed to be independent. For each episode, we considered:</p><sec id="ss6"><title>Virus detection</title><p>The presence or absence of detectable virus in a respiratory specimen was categorised as a binary outcome measure. Associations were sought between virus detection and a number of participant (age, sex, race, smoking and vaccine status) and spatio&#x02010;temporal (month and study site) variables, using multivariate logistic regression modelling.</p><p>Virological results were then organised into broad groupings: none (no virus detected), picornaviruses, influenza viruses (A and B), coronaviruses and other (hMPV, parainfluenza viruses, RSV, adenoviruses, bocaviruses and polyomaviruses). For each virus group, associations with host and external variables were described.</p></sec><sec id="ss7"><title>Symptom score</title><p>The symptom scores developed by Hayden <italic>et&#x000a0;al.</italic>
<xref rid="b29" ref-type="ref">
<sup>29</sup>
</xref> in trials of the influenza drug Oseltamivir, while ideal, were considered too labour intensive to be applied in this protocol. We therefore sought to encapsulate the most comprehensive range of symptoms possible for characterisation and comparison of illness episodes. For participants who returned the questionnaire, a &#x02018;symptom score&#x02019; was calculated by scoring one point for each symptom, ranging from a minimum of 2 (necessary to meet the case definition) to a maximum of 16. Associations between this score and the virus isolated (by group), host factors (age, sex, race and smoking) or spatio&#x02010;temporal (month and study site) variables were considered using multivariate linear regression models. Vaccination status of participants was not (and cannot be) included in the regression models because of its known mitigating effect on the likelihood of influenza acquisition (see<xref rid="ss8" ref-type="sec">Results</xref>).</p><p>Measures of episode severity including medically diagnosed complications, medical attendance (and practitioner type), prescription of antiviral agents, duration of episode and number of days away from usual activity as a result of illness were reported.</p><p>All statistical analyses were conducted using <sc>stata</sc>/<sc>ic</sc> 11&#x000b7;1 (StataCorp LP, College Station, TX, USA).</p></sec></sec></sec><sec id="ss8"><title>Results</title><sec id="ss9"><title>Study population</title><p>Consent to participate in the substudy was obtained during 651 of 676 attended illness episodes in the main industry&#x02010;sponsored RCT. The 651 episodes occurred in 586 participants. As eight specimens were missing, only 643 samples from 581 participants were included in the analysis of virus isolation (Virology Data set). Self&#x02010;completed questionnaires detailing the clinical course of 336 illness episodes were returned by 308 participants. A virus sample was associated with 322 of these questionnaires (Questionnaire Data set) (<xref rid="f1" ref-type="fig">Figure&#x000a0;1</xref>).</p><p>Demographic characteristics of individual participants in each of these two study populations are summarised in <xref rid="t1" ref-type="table-wrap">Table&#x000a0;1</xref>. A number of participant factors were associated with increased probability of completion of the questionnaire: female sex (RR&#x02003;=&#x02003;1&#x000b7;13 (0&#x000b7;99, 1&#x000b7;30), <italic>P&#x02003;</italic>=<italic>&#x02003;</italic>0&#x000b7;07), older age (<italic>P&#x02003;</italic>&#x0003c;<italic>&#x02003;</italic>0&#x000b7;001 in an omnibus test across age categories versus questionnaire completion) and vaccination (RR&#x02003;=&#x02003;1&#x000b7;13 (1&#x000b7;00, 1&#x000b7;28), <italic>P&#x02003;</italic>=<italic>&#x02003;</italic>0&#x000b7;05). Similarly, an omnibus test for an association with smoking is statistically significant (<italic>P&#x02003;</italic>=<italic>&#x02003;</italic>0&#x000b7;001) but the proportion who have &#x02018;never&#x02019; smoked is very similar (160 of 274 (58&#x000b7;4%) versus 186 of 307 (60&#x000b7;6%) in the two data sets.</p><table-wrap id="t1" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Characteristics of study participants</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" valign="bottom" align="left" colspan="1">Characteristics</th><th style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1" colspan="1">Virology data set</th><th style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1" colspan="1">Questionnaire data set</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic>n</italic> (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic>n</italic> (%)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Total participants</td><td align="left" valign="top" rowspan="1" colspan="1">581 (100)</td><td align="left" valign="top" rowspan="1" colspan="1">308 (100)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex (female)</td><td align="left" valign="top" rowspan="1" colspan="1">343 (59&#x000b7;0)</td><td align="left" valign="top" rowspan="1" colspan="1">193 (62&#x000b7;7)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Race</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Caucasian</td><td align="left" valign="top" rowspan="1" colspan="1">525 (90&#x000b7;4)</td><td align="left" valign="top" rowspan="1" colspan="1">279 (90&#x000b7;6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Asian</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;40 (6&#x000b7;9)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;20 (6&#x000b7;5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Other/Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;16 (2&#x000b7;8)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;9 (2&#x000b7;9)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Smoking status</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Current</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;76 (13&#x000b7;1)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;26 (8&#x000b7;4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Ever</td><td align="left" valign="top" rowspan="1" colspan="1">149 (25&#x000b7;7)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;93 (30&#x000b7;2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Never</td><td align="left" valign="top" rowspan="1" colspan="1">346 (59&#x000b7;6)</td><td align="left" valign="top" rowspan="1" colspan="1">184 (59&#x000b7;7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;10 (1&#x000b7;7)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;5 (1&#x000b7;6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vaccine recipients</td><td align="left" valign="top" rowspan="1" colspan="1">374 (64&#x000b7;4)</td><td align="left" valign="top" rowspan="1" colspan="1">211 (68&#x000b7;5)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Age (years)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;18&#x02013;24</td><td align="left" valign="top" rowspan="1" colspan="1">192 (33&#x000b7;0)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;89 (28&#x000b7;9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;25&#x02013;34</td><td align="left" valign="top" rowspan="1" colspan="1">115 (19&#x000b7;8)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;39 (12&#x000b7;7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;35&#x02013;44</td><td align="left" valign="top" rowspan="1" colspan="1">110 (18&#x000b7;9)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;70 (22&#x000b7;7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;45&#x02013;54</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;94 (16&#x000b7;2)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;59 (19&#x000b7;2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;55&#x02013;64</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;70 (12&#x000b7;0)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;51 (16&#x000b7;6)</td></tr></tbody></table></table-wrap></sec><sec id="ss10"><title>Virus detection</title><p>A known virus was identified from 284 of 643 (44&#x000b7;2%) specimens in the Virology Data set. These viruses are listed in <xref rid="t2" ref-type="table-wrap">Table&#x000a0;2</xref>, together with groupings for the purpose of further analysis given small numbers in many instances. The overall distribution of viruses isolated (by group) varied substantially by month of collection, with picornaviruses the most common in May, coronaviruses isolated predominantly in June&#x02013;August and influenza viruses detected primarily in August&#x02013;September (<xref rid="f2" ref-type="fig">Figure&#x000a0;2</xref>).</p><table-wrap id="t2" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Viruses identified from influenza&#x02010;like illness swabs, by PCR</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Virus group</th><th align="left" valign="bottom" rowspan="1" colspan="1">PCR result</th><th colspan="2" align="left" valign="bottom" rowspan="1">Virology data set (<italic>n</italic>&#x02003;=&#x02003;643 specimens)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">None</td><td align="left" valign="top" rowspan="1" colspan="1">No virus detected</td><td align="left" valign="top" rowspan="1" colspan="1">359</td><td align="left" valign="top" rowspan="1" colspan="1">55&#x000b7;8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Picorna</td><td align="left" valign="top" rowspan="1" colspan="1">Picornaviruses</td><td align="left" valign="top" rowspan="1" colspan="1">144</td><td align="left" valign="top" rowspan="1" colspan="1">22&#x000b7;4</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Flu</td><td align="left" valign="top" rowspan="1" colspan="1">Influenza A</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;29</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;4&#x000b7;5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Influenza B</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;39</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;6&#x000b7;1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Corona</td><td align="left" valign="top" rowspan="1" colspan="1">Coronaviruses</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;35</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;5&#x000b7;4</td></tr><tr><td rowspan="5" valign="top" align="left" colspan="1">Other</td><td align="left" valign="top" rowspan="1" colspan="1">Human metapneumovirus</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;11</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;1&#x000b7;7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Parainfluenza viruses</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;11</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;1&#x000b7;7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Respiratory syncytial virus</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;8</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;1&#x000b7;2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Adenovirus</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;3</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;0&#x000b7;5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Other viruses*</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;4</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;0&#x000b7;6</td></tr></tbody></table><table-wrap-foot><fn id="t2_note38"><p>*Other viruses include bocaviruses, polyomaviruses.</p></fn></table-wrap-foot></table-wrap><fig fig-type="Figure" xml:lang="en" id="f2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>&#x02002;Viruses identified, by month of specimen collection.</p></caption><graphic id="nlm-graphic-3" xlink:href="IRV-7-330-g002"/></fig><p>Associations were sought between a range of participant variables and positive virus identification considering the illness episode as the primary unit of analysis, adjusted for month of collection and study site (<xref rid="t3" ref-type="table-wrap">Table&#x000a0;3</xref>). Adults aged 25&#x02013;34&#x02003;years and 45&#x02013;54&#x02003;years were significantly less likely to have a virus detected by PCR than the reference age group of 18&#x02013;24&#x02003;years. Specimen positivity was not associated with the time gap between ILI onset and specimen collection and was consistent throughout the study period, with no effect of month observed. Of note, three of the four highest recruiting sites reported significantly lower adjusted odds ratios for a detectable virus, with between 35&#x000b7;6% and 41&#x000b7;6% of specimens returning a result compared with the fourth (the reference site) where 53 of 103 (51&#x000b7;5%) of specimens tested positive (data not shown).</p><table-wrap id="t3" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Multivariate logistic regression model, reporting associations with positive virus detection in respiratory specimens</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Variable</th><th align="left" valign="bottom" rowspan="1" colspan="1">Adjusted OR* (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic>&#x02010;value</th><th align="left" valign="bottom" rowspan="1" colspan="1">Virus not detected <italic>n</italic> (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Virus detected <italic>n</italic> (%)</th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" rowspan="1">Age (ref: 18&#x02013;24&#x02003;years)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;18&#x02013;24&#x02003;years</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">113 (31&#x000b7;5)</td><td align="left" valign="top" rowspan="1" colspan="1">103 (36&#x000b7;2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;
<bold>25&#x02013;34&#x02003;years</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0&#x000b7;51</bold> (<bold>0&#x000b7;31, 0&#x000b7;83</bold>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0&#x000b7;01</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x02002;84</bold> (<bold>23&#x000b7;4</bold>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x02002;47</bold> (<bold>16&#x000b7;5</bold>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;35&#x02013;44&#x02003;years</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;93 (0&#x000b7;57, 1&#x000b7;5)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;8</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;60 (16&#x000b7;7)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;63 (22&#x000b7;2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;
<bold>45&#x02013;54&#x02003;years</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0&#x000b7;52</bold> (<bold>0&#x000b7;30, 0&#x000b7;90</bold>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0&#x000b7;02</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x02002;60</bold> (<bold>16&#x000b7;7</bold>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x02002;40</bold> (<bold>14&#x000b7;1</bold>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;55&#x02013;64&#x02003;years</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;61 (0&#x000b7;33, 1&#x000b7;1)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;1</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;42 (11&#x000b7;7)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;31 (10&#x000b7;9)</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Sex (ref: male)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Male</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">155 (43&#x000b7;2)</td><td align="left" valign="top" rowspan="1" colspan="1">112 (39&#x000b7;4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Female</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;1&#x000b7;2 (0&#x000b7;88, 1&#x000b7;7)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;2</td><td align="left" valign="top" rowspan="1" colspan="1">204 (56&#x000b7;8)</td><td align="left" valign="top" rowspan="1" colspan="1">172 (60&#x000b7;6)</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Race (ref: Caucasian)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Caucasian</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">327 (91&#x000b7;1)</td><td align="left" valign="top" rowspan="1" colspan="1">252 (88&#x000b7;7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Asian</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;1&#x000b7;4 (0&#x000b7;72, 2&#x000b7;6)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;3</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;23 (6&#x000b7;4)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;23 (8&#x000b7;1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Other</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;1&#x000b7;5 (0&#x000b7;56, 4&#x000b7;2)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;4</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;9 (2&#x000b7;5)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;9 (3&#x000b7;2)</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Smoking status (ref: Current)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Current</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;43 (12&#x000b7;0)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;36 (12&#x000b7;7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Ever</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;88 (0&#x000b7;49, 1&#x000b7;6)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;6</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;91 (25&#x000b7;3)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;77 (27&#x000b7;1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Never</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;70 (0&#x000b7;41, 1&#x000b7;2)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;2</td><td align="left" valign="top" rowspan="1" colspan="1">217 (60&#x000b7;4)</td><td align="left" valign="top" rowspan="1" colspan="1">169 (59&#x000b7;5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;16 (0&#x000b7;03, 0&#x000b7;88)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;04</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;8 (2&#x000b7;2)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;2 (0&#x000b7;7)</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Vaccinated (ref: placebo)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Placebo</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">132 (36&#x000b7;8)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;99 (34&#x000b7;9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Vaccine</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;1&#x000b7;1 (0&#x000b7;77, 1&#x000b7;55)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;6</td><td align="left" valign="top" rowspan="1" colspan="1">227 (63&#x000b7;2)</td><td align="left" valign="top" rowspan="1" colspan="1">185 (65&#x000b7;1)</td></tr></tbody></table><table-wrap-foot><fn id="t3_note90"><p>*Adjusted for month of collection and study site. Bold text indicates <italic>P</italic> &#x0003c; 0.05.</p></fn></table-wrap-foot></table-wrap><p>As can be seen from <xref rid="t4" ref-type="table-wrap">Table&#x000a0;4</xref>, participant characteristics were not associated with the detection of one virus group over another, with the predictable exception of influenza vaccination status. In a univariate logistic regression model with vaccination status as the outcome variable, individuals testing positive for influenza viruses were significantly less likely to have been immunised than the reference (virus negative) population (OR&#x02003;=&#x02003;0&#x000b7;52 (0&#x000b7;31, 0&#x000b7;87) <italic>P&#x02003;</italic>=<italic>&#x02003;</italic>0&#x000b7;01), indicating a protective effect (against ILI) of the vaccine. There was also a trend towards higher immunisation coverage among those in whom picornaviruses were detected (OR&#x02003;=&#x02003;1&#x000b7;5 (0&#x000b7;99, 2&#x000b7;3) <italic>P&#x02003;</italic>=<italic>&#x02003;</italic>0&#x000b7;06). Given no association between the reference (virus negative) and vaccination [OR&#x02003;=&#x02003;0&#x000b7;92 (0&#x000b7;67, 1&#x000b7;3) <italic>P&#x02003;</italic>=<italic>&#x02003;</italic>0&#x000b7;6], this finding indicates an association between picornavirus detection and vaccinated participants. Prior to the influenza season (defined as months August and September), this association between picornavirus detection and influenza vaccination was not evident [OR&#x02003;=&#x02003;1&#x000b7;3 (0&#x000b7;73, 2&#x000b7;3) <italic>P&#x02003;</italic>=<italic>&#x02003;</italic>0&#x000b7;38], while during and following the season the association was stronger [OR&#x02003;=&#x02003;2&#x000b7;0. (1&#x000b7;1, 3&#x000b7;6) <italic>P&#x02003;</italic>=<italic>&#x02003;</italic>0&#x000b7;02].</p><table-wrap id="t4" xml:lang="en" orientation="portrait" position="float"><label>Table 4</label><caption><p>Characteristics of participants, by virus group</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Variable</th><th align="left" valign="bottom" rowspan="1" colspan="1">No virus detected (<italic>n</italic>&#x02003;=&#x02003;359)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Picornaviruses (<italic>n</italic>&#x02003;=&#x02003;144)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Influenza A&#x00026;B (<italic>n</italic>&#x02003;=&#x02003;68)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Coronaviruses (<italic>n</italic>&#x02003;=&#x02003;35)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Other viruses (<italic>n</italic>&#x02003;=&#x02003;37)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean age (SD) in years</td><td align="left" valign="top" rowspan="1" colspan="1">35&#x000b7;5 (13&#x000b7;7)</td><td align="left" valign="top" rowspan="1" colspan="1">34&#x000b7;0 (13&#x000b7;2)</td><td align="left" valign="top" rowspan="1" colspan="1">33&#x000b7;6 (13&#x000b7;1)</td><td align="left" valign="top" rowspan="1" colspan="1">37&#x000b7;9 (16&#x000b7;3)</td><td align="left" valign="top" rowspan="1" colspan="1">38&#x000b7;8 (14&#x000b7;2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex (% female)</td><td align="left" valign="top" rowspan="1" colspan="1">56&#x000b7;8</td><td align="left" valign="top" rowspan="1" colspan="1">61&#x000b7;8</td><td align="left" valign="top" rowspan="1" colspan="1">53&#x000b7;0</td><td align="left" valign="top" rowspan="1" colspan="1">60&#x000b7;0</td><td align="left" valign="top" rowspan="1" colspan="1">70&#x000b7;3</td></tr><tr><td colspan="6" align="left" valign="top" rowspan="1">Race</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Caucasian</td><td align="left" valign="top" rowspan="1" colspan="1">91&#x000b7;1%</td><td align="left" valign="top" rowspan="1" colspan="1">87&#x000b7;5%</td><td align="left" valign="top" rowspan="1" colspan="1">94&#x000b7;1%</td><td align="left" valign="top" rowspan="1" colspan="1">85&#x000b7;7%</td><td align="left" valign="top" rowspan="1" colspan="1">86&#x000b7;5%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Asian</td><td align="left" valign="top" rowspan="1" colspan="1">6&#x000b7;4%</td><td align="left" valign="top" rowspan="1" colspan="1">9&#x000b7;0%</td><td align="left" valign="top" rowspan="1" colspan="1">3&#x000b7;0%</td><td align="left" valign="top" rowspan="1" colspan="1">8&#x000b7;6%</td><td align="left" valign="top" rowspan="1" colspan="1">13&#x000b7;5%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Other</td><td align="left" valign="top" rowspan="1" colspan="1">2&#x000b7;5%</td><td align="left" valign="top" rowspan="1" colspan="1">3&#x000b7;5%</td><td align="left" valign="top" rowspan="1" colspan="1">2&#x000b7;9%</td><td align="left" valign="top" rowspan="1" colspan="1">5&#x000b7;7%</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td></tr><tr><td colspan="6" align="left" valign="top" rowspan="1">Smoking status</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Current</td><td align="left" valign="top" rowspan="1" colspan="1">12&#x000b7;0%</td><td align="left" valign="top" rowspan="1" colspan="1">11&#x000b7;8%</td><td align="left" valign="top" rowspan="1" colspan="1">11&#x000b7;8%</td><td align="left" valign="top" rowspan="1" colspan="1">11&#x000b7;4%</td><td align="left" valign="top" rowspan="1" colspan="1">18&#x000b7;9%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Ever</td><td align="left" valign="top" rowspan="1" colspan="1">25&#x000b7;4%</td><td align="left" valign="top" rowspan="1" colspan="1">23&#x000b7;6%</td><td align="left" valign="top" rowspan="1" colspan="1">30&#x000b7;9%</td><td align="left" valign="top" rowspan="1" colspan="1">28&#x000b7;6%</td><td align="left" valign="top" rowspan="1" colspan="1">32&#x000b7;4%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Never</td><td align="left" valign="top" rowspan="1" colspan="1">60&#x000b7;4%</td><td align="left" valign="top" rowspan="1" colspan="1">63&#x000b7;9%</td><td align="left" valign="top" rowspan="1" colspan="1">55&#x000b7;9%</td><td align="left" valign="top" rowspan="1" colspan="1">60&#x000b7;0%</td><td align="left" valign="top" rowspan="1" colspan="1">48&#x000b7;7%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">2&#x000b7;2%</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;7%</td><td align="left" valign="top" rowspan="1" colspan="1">1&#x000b7;5%</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">% Vaccinated</td><td align="left" valign="top" rowspan="1" colspan="1">63&#x000b7;2%</td><td align="left" valign="top" rowspan="1" colspan="1">72&#x000b7;2%</td><td align="left" valign="top" rowspan="1" colspan="1">47&#x000b7;1%*</td><td align="left" valign="top" rowspan="1" colspan="1">60&#x000b7;0%</td><td align="left" valign="top" rowspan="1" colspan="1">75&#x000b7;7%</td></tr></tbody></table><table-wrap-foot><fn id="t4_note68"><p>*<italic>P</italic>&#x02003;&#x0003c;&#x02003;0&#x000b7;05 as assessed by univariate regression (linear, ordinal or logistic as appropriate).</p></fn></table-wrap-foot></table-wrap></sec><sec id="ss11"><title>Recorded symptoms</title><p>Individual symptoms reported by participants at each episode are summarised in <xref rid="t5" ref-type="table-wrap">Table&#x000a0;5</xref>, along with medically diagnosed complications of ILI. Twenty&#x02010;eight participants experienced repeated infections over the study period (two episodes in 25, three episodes in three subjects). The same virus group (picornaviruses) was only isolated on more than one occasion from two participants, in each instance more than 6&#x02003;weeks apart, justifying their consideration as independent events. The median duration of illness was 6&#x02003;days (range 1, 51) with no significant variation by virus type (data not shown). The median time spent away from usual activity was 2&#x02003;days (range 0, 14), with an increase in the mean of 1&#x000b7;3&#x02003;days (0&#x000b7;5, 2&#x000b7;2; <italic>P&#x02003;</italic>=<italic>&#x02003;</italic>0&#x000b7;001) in episodes associated with isolation of influenza compared to episodes with virus&#x02010;negative isolates in a univariate linear regression model. In all, 94 episodes were medically attended, of which 83 were visits to the general practitioner. No association with virus type was observed (logistic regression, data not shown). Thirteen participants were prescribed antiviral medication; none were hospitalised. Small numbers of recorded medically diagnosed complications (<xref rid="t5" ref-type="table-wrap">Table&#x000a0;5</xref>) prevented any detailed analysis of associations with virus isolation, but we note a weak suggestion that bronchitis (9%) and &#x02018;chest infection&#x02019; (12%) were more common in participants with influenza than overall (cf, 2&#x000b7;4% and 7&#x000b7;4%, <xref rid="t5" ref-type="table-wrap">Table&#x000a0;5</xref>).</p><table-wrap id="t5" xml:lang="en" orientation="portrait" position="float"><label>Table 5</label><caption><p>Reported symptoms and complications in 336 illness episodes</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Symptoms</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic>n</italic> (%)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Fever (&#x02265;37&#x000b7;8&#x000b0;C)</td><td align="left" valign="top" rowspan="1" colspan="1">136 (40&#x000b7;4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Feverish</td><td align="left" valign="top" rowspan="1" colspan="1">214 (63&#x000b7;5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chills</td><td align="left" valign="top" rowspan="1" colspan="1">199 (59&#x000b7;1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Myalgia</td><td align="left" valign="top" rowspan="1" colspan="1">272 (80&#x000b7;7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Headache</td><td align="left" valign="top" rowspan="1" colspan="1">253 (75&#x000b7;1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Less active</td><td align="left" valign="top" rowspan="1" colspan="1">241 (71&#x000b7;5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Irritability</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;89 (26&#x000b7;4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cough</td><td align="left" valign="top" rowspan="1" colspan="1">234 (69&#x000b7;4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Productive cough</td><td align="left" valign="top" rowspan="1" colspan="1">106 (31&#x000b7;5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Shortness of breath</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;64 (19&#x000b7;0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wheeze</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;64 (19&#x000b7;0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sore throat</td><td align="left" valign="top" rowspan="1" colspan="1">261 (77&#x000b7;4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Blocked nose</td><td align="left" valign="top" rowspan="1" colspan="1">196 (58&#x000b7;2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Runny nose</td><td align="left" valign="top" rowspan="1" colspan="1">241 (71&#x000b7;5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vomiting</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;20 (5&#x000b7;9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02018;Pneumonia&#x02019;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;1 (0&#x000b7;3)</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">Complications</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Otitis media</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;4 (1&#x000b7;2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Sinusitis</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;12 (3&#x000b7;6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Bronchitis</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;8 (2&#x000b7;4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Chest infection</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;25 (7&#x000b7;4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Pneumonia</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;1 (0&#x000b7;3)</td></tr></tbody></table></table-wrap><p>Observed values for the symptom score were normally distributed, with a mean of 7&#x000b7;7 (SD 2&#x000b7;5) and median of 7 (range 2&#x02013;15). Associations were sought between this continuous outcome and virus and participant characteristics in a multivariate linear regression model, adjusted for month and site of specimen collection (<xref rid="t6" ref-type="table-wrap">Table&#x000a0;6</xref>).</p><table-wrap id="t6" xml:lang="en" orientation="portrait" position="float"><label>Table 6</label><caption><p>Multivariate linear regression model, reporting associations between virus group, participant characteristics and symptom score</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Variables</th><th align="left" valign="bottom" rowspan="1" colspan="1">Mean Score (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Adjusted coefficient* (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic>&#x02010;value</th></tr></thead><tbody valign="top"><tr><td colspan="4" align="left" valign="top" rowspan="1">Virus Group (ref: None)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;None</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;7&#x000b7;5 (7&#x000b7;1, 7&#x000b7;8)</td><td align="left" valign="top" rowspan="1" colspan="1">Ref</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Picorna</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;7&#x000b7;4 (6&#x000b7;8, 8&#x000b7;0)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0&#x000b7;04 (&#x02212;0&#x000b7;72, 0&#x000b7;65)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;
<bold>Influenza</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>10&#x000b7;2</bold> (<bold>9&#x000b7;4, 10&#x000b7;9</bold>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x02003;2&#x000b7;6</bold> (<bold>1&#x000b7;6, 3&#x000b7;6</bold>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c;0&#x000b7;001</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Corona</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;7&#x000b7;3 (6&#x000b7;2, 8&#x000b7;3)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0&#x000b7;11 (&#x02212;1&#x000b7;5, 1&#x000b7;3)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Other</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;7&#x000b7;7 (6&#x000b7;5, 8&#x000b7;9)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;0&#x000b7;26 (&#x02212;0&#x000b7;85, 1&#x000b7;4)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;6</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Age (ref: 18&#x02013;24&#x02003;years)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;18&#x02013;24&#x02003;years</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;7&#x000b7;9 (7&#x000b7;4, 8&#x000b7;3)</td><td align="left" valign="top" rowspan="1" colspan="1">Ref</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;25&#x02013;34&#x02003;years</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;7&#x000b7;6 (6&#x000b7;9, 8&#x000b7;3)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0&#x000b7;37 (&#x02212;1&#x000b7;3, 0&#x000b7;55)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;35&#x02013;44&#x02003;years</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;7&#x000b7;6 (7&#x000b7;0, 8&#x000b7;2)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0&#x000b7;48 (&#x02212;1&#x000b7;3, 0&#x000b7;34)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;45&#x02013;54&#x02003;years</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;7&#x000b7;5 (6&#x000b7;9, 8&#x000b7;2)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0&#x000b7;21 (&#x02212;1&#x000b7;1, 0&#x000b7;69)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;55&#x02013;64&#x02003;years</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;8&#x000b7;0 (7&#x000b7;1, 8&#x000b7;8)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;0&#x000b7;14 (&#x02212;0&#x000b7;83, 1&#x000b7;1)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;8</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Sex (ref: male)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Male</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;7&#x000b7;7 (7&#x000b7;2, 8&#x000b7;1)</td><td align="left" valign="top" rowspan="1" colspan="1">Ref</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Female</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;7&#x000b7;7 (7&#x000b7;4, 8&#x000b7;1)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;0&#x000b7;40 (&#x02212;0&#x000b7;19, 1&#x000b7;0)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;2</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Race (ref: Caucasian)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Caucasian</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;7&#x000b7;8 (7&#x000b7;5, 8&#x000b7;1)</td><td align="left" valign="top" rowspan="1" colspan="1">Ref</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;
<bold>Asian</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x02002;6&#x000b7;3</bold> (<bold>5&#x000b7;3, 7&#x000b7;3</bold>)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;
<bold>&#x02212;1&#x000b7;4</bold> (<bold>&#x02212;2&#x000b7;5, &#x02010;0&#x000b7;26</bold>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0&#x000b7;02</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Other</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;7&#x000b7;1 (5&#x000b7;5, 8&#x000b7;8)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0&#x000b7;34 (&#x02212;2&#x000b7;2, 1&#x000b7;5)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;7</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Smoking status (ref: Current)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Current</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;7&#x000b7;6 (6&#x000b7;6, 8&#x000b7;7)</td><td align="left" valign="top" rowspan="1" colspan="1">Ref</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Ever</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;7&#x000b7;9 (7&#x000b7;4, 8&#x000b7;4)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;0&#x000b7;07 (&#x02212;1&#x000b7;0, 1&#x000b7;2)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Never</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;7&#x000b7;6 (7&#x000b7;2, 7&#x000b7;9)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0&#x000b7;01 (&#x02212;1&#x000b7;1, 1&#x000b7;0)</td><td align="left" valign="top" rowspan="1" colspan="1">1&#x000b7;0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;9&#x000b7;6 (4&#x000b7;7, 14&#x000b7;5)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0&#x000b7;43 (&#x02212;3&#x000b7;4, 2&#x000b7;6)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;8</td></tr></tbody></table><table-wrap-foot><fn id="t6_note85"><p>*Adjusted for month of collection and study site. Bold text indicates <italic>P</italic> &#x0003c; 0.05.</p></fn></table-wrap-foot></table-wrap><p>The mean symptom score reported by individuals with influenza was significantly higher than that observed in ILIs attributed to other infectious causes, or where no virus was detected. This score was not attenuated by vaccination status, in a post hoc subgroup analysis restricted to influenza&#x02010;positive episodes [Vaccinated mean score: 9&#x000b7;9, Unvaccinated mean score: 10&#x000b7;3; Difference (95% CI): &#x02212;0&#x000b7;38 (&#x02212;1&#x000b7;9, 1&#x000b7;1); <italic>P&#x02003;</italic>=<italic>&#x02003;</italic>0&#x000b7;61]. Asian participants reported significantly fewer symptoms than Caucasians for non&#x02010;influenza presentations [Asian mean score: 6&#x000b7;30, Caucasian mean score: 7&#x000b7;52; Difference (95% CI):&#x02212;1&#x000b7;2 (&#x02212;2&#x000b7;2, 0&#x000b7;20); <italic>P&#x02003;</italic>=<italic>&#x02003;</italic>0&#x000b7;02]. No Asian participants who had influenza completed the questionnaire, preventing further analysis. Symptom scores were consistent throughout the year, with no effect of month of presentation observed. Participants at two study sites reported significantly higher symptom scores than at other centres &#x02013; on further inspection, these results were likely due to small numbers, involving a total of 25 participants, of whom three had influenza.</p></sec></sec><sec id="ss12"><title>Discussion</title><p>Over the course of the study period, approximately 10% of participants presented for ILI evaluation and half of these provided additional information on the course of their disease. A known virus was identified in 44% of samples, with varying detection rates by age and site. For isolates with undetectable virus, we cannot distinguish between inadequate sampling from the participant, issues relating to transport of the sample, or presence of an unknown virus. Picornaviruses were the most common viruses observed followed by influenza. While influenza was only confirmed in approximately 2% of the placebo&#x02010;group participants, the 2008 influenza season in Australia was particularly mild, following on from the notably severe 2007 seasonal epidemic.<xref rid="b30" ref-type="ref">
<sup>30</sup>
</xref> Given this, however, we do acknowledge that under&#x02010;ascertainment may have occurred as a result of subclinical infections and potential failure of participants to report mild symptoms, despite intensive follow&#x02010;up.</p><p>Consistent with expectations and findings in healthy children in which influenza was associated with higher severity,<xref rid="b31" ref-type="ref">
<sup>31</sup>
</xref> here influenza was associated with a higher composite &#x02018;symptom score&#x02019;. Vaccination provided partial protection against ILI associated with influenza, but there was no evidence of disease modification (as measured by symptom score) in participants with breakthrough symptomatic infection. We speculate that this may be due to infection with a strain of influenza not covered by the vaccine. In a further study of household transmission (in preparation) using the Questionnaire data set, we find further evidence consistent with this hypothesis, although without further virus typing, cannot subject our hypothesis to further scrutiny.</p><p>The observed association between vaccination and isolation of picornaviruses perhaps suggests that picornaviruses are filling the niche vacated by exclusion of influenza owing to vaccination, consistent with the hypothesis of viral interference.<xref rid="b32" ref-type="ref">
<sup>32</sup>
</xref> Support for the association is present during and following the influenza season but not prior to the season, consistent with an interference effect, although we cannot exclude other explanations, including simple statistical fluctuation.</p><p>Our study was conducted within a large, community dwelling cohort of healthy adults and used a non&#x02010;specific and sensitive (i.e. inclusive) ILI case definition to ascertain presentations across the full spectrum of symptomatic disease.<xref rid="b33" ref-type="ref">
<sup>33</sup>
</xref> It therefore complements protocols that have focused on individuals with underlying respiratory disorders presenting for medical care in outpatient or hospital settings,<xref rid="b34" ref-type="ref">
<sup>34</sup>
</xref> to provide a more comprehensive picture of the spectrum of symptomatic disease. The diagnostic methods (PCR) employed were of high specificity and allowed us to test for a large number of recently described pathogens, reducing the probability of returning a negative result.</p><p>As the study was conducted within an industry&#x02010;sponsored trial of vaccine effectiveness, it was necessarily constrained by the primary protocol to some degree. Participants were selected to be &#x02018;healthy&#x02019;, without underlying conditions that would have resulted in a routine recommendation for annual influenza vaccination, given the placebo&#x02010;controlled study design. The study population varies from the general population, being younger, less likely to smoke and more likely to be women. Furthermore, the study population who returned a questionnaire, enabling an examination of symptom score, was further biased towards women and those 35&#x02003;years and over. Two&#x02010;thirds of participants were immunised against influenza, associated with the anticipated reduction in influenza cases in the vaccinated proportion. Swabs were only collected from individuals presenting for ILI evaluation, and not from a &#x02018;control&#x02019; population. This limited our ability to assert pathogenicity of the viruses detected and restricts our comparison of &#x02018;symptom scores&#x02019; by virus to only those infection events in which participants met (and reported) the ILI case definition.</p><p>A study conducted using a General Practice sentinel surveillance scheme in Victoria, Australia in the same year (2008)<xref rid="b35" ref-type="ref">
<sup>35</sup>
</xref> showed a similar overall rate for virus detection (43%) in those ILI&#x02019;s submitted for swabbing (46% of all ILIs reported by the GPs in the study), despite a smaller number of viruses tested for. In that study, 29% of all specimens were positive for influenza, compared with 11% here. The mix of viruses detected in the 83 participants in our study who presented to a GP was similar to the full data set (data not shown). These discrepancies perhaps reflect the non&#x02010;specific nature of the ILI definition used in our study or a potential bias in the ILIs chosen to be swabbed by the GPs in the study by Grant <italic>et&#x000a0;al.</italic>
<xref rid="b35" ref-type="ref">
<sup>35</sup>
</xref>
</p><p>Compared with a case&#x02013;control study of respiratory viruses involved with exacerbations of chronic obstructive pulmonary disease (COPD) conducted in Melbourne, Australia, our overall rate of virus detection was higher (21% of exacerbations in that study) and the distribution of viruses, with a preponderance of picornaviruses and influenza similar.<xref rid="b36" ref-type="ref">
<sup>36</sup>
</xref> That study confirmed far greater odds of virus detection in individuals with symptoms than matched controls, providing prior evidence of the aetiological role of viruses in illness exacerbations, as did a similar study in Germany where picornaviruses, influenza and RSV most commonly caused disease.<xref rid="b37" ref-type="ref">
<sup>37</sup>
</xref> Among patients with COPD in Belfast, rhinoviruses and adenovirus were most frequently associated with increasing respiratory difficulty.<xref rid="b38" ref-type="ref">
<sup>38</sup>
</xref> A study in a similar patient population in Hong Kong revealed a far lower burden of picornaviruses (rhinovirus), perhaps reflecting true differences in epidemiology, or differing sensitivity of detection methods.<xref rid="b39" ref-type="ref">
<sup>39</sup>
</xref>
</p><p>Our findings add to an evolving knowledge base regarding the experience of a range of respiratory viruses in Australia.<xref rid="b19" ref-type="ref">
<sup>19</sup>
</xref>, <xref rid="b40" ref-type="ref">
<sup>40</sup>
</xref> In particular, they confirm a distinction between influenza and other pathogens (as measured by a symptom score) even among healthy individuals, which has led to calls for expansion of funded immunisation recommendations in Australia to reduce the spread of disease.<xref rid="b41" ref-type="ref">
<sup>41</sup>
</xref> More data such as ours are required to fill existing knowledge gaps regarding the community burden of disease to inform more robust estimates of the likely cost&#x02010;effectiveness of such strategies.<xref rid="b42" ref-type="ref">
<sup>42</sup>
</xref>
</p><p>In further work, we will consider the household&#x02010;level impact of infection introduction, by examining patterns of secondary transmission described in participant questionnaires. Having identified specimens testing negative for all known viruses, the next phase of this project involves discovery of hitherto unknown respiratory viruses using broad&#x02010;range viral molecular detection methods.</p></sec><sec id="ss13"><title>Authorship addendum</title><p>Peter Howard, James McCaw and Jodie McVernon conducted the statistical analyses, provided the primary interpretation of the results and wrote the manuscript. Peter Richmond was principal investigator on the vaccine efficacy trial within which the substudy was conducted. Terry Nolan, Jodie McVernon, Theo Sloots, Michael Nissen, Stephen Lambert and Peter Richmond conceived the substudy and secured funding for its conduct, in partnership with CSL Limited represented by Michael Lai and Michael Greenberg. Jodie McVernon coordinated conduct of the study at multiple sites and oversaw collation of the questionnaire data. Theo Sloots, Michael Nissen and Stephen Lambert oversaw conduct of and reporting of the virological testing at the Queensland Paediatric Infectious Diseases Laboratory. Michael Lai was medical monitor for the main vaccine study and a partner investigator on the substudy, as was Michael Greenberg. All authors contributed to critical revision of the manuscript and have seen and approved the final version of the manuscript.</p></sec><sec id="ss15"><title>Conflict of interest</title><p>MN has received travel grants from Wyeth Australia to present independent research at international meetings, and currently and previously has been the principal investigator for clinical trials sponsored by Abbott, Baxter, CSL, GSK, MedImmune, Merck, Novartis, Sanofi&#x02010;Pasteur, Wyeth, and Pfizer.</p></sec></body><back><ack id="ss14"><title>Acknowledgements</title><p>We thank study staff at the 12 sites for the recruitment of participants and collection of and processing of samples for this substudy. We thank Dale Cooper (CSL Limited) for facilitating study conduct including provision of study data collected by CSL as part of the main vaccine study. Terry Nolan (Vaccination and Immunisation Research Group, Melbourne, Victoria), Peter Richmond (Telethon Institute for Child Health Research, Perth, Western Australia), Jeff Karrasch (Australian Clinical Research Organisation, four sites across Queensland NSW), Helen Marshall (Adelaide Women&#x02019;s and Children&#x02019;s Hospital, Adelaide, South Australia), Sepehr Shakib (CMAX, Adelaide, South Australia), Fred de Looze (Queensland Trialworks, Queensland), John McBride (James Cook University, Cairns, Queensland), Maree O&#x02019;Sullivan (Hobart Sexual Health Service, Hobart, Tasmania) and Walter Abhayaratna (Australian National University, Canberra, Australian Capital Territory) led the investigation at participating sites. We thank Dr Julie Simpson for statistical advice. This research was supported by an Australian Research Council Linkage Project (LP0989464) with support from CSL Limited, Victoria, Australia. Jodie McVernon is supported by a National Health and Medical Research Council (Australia) Career Development Award (566635).</p></ack><ref-list id="ss16"><title>References</title><ref id="b1"><label>1</label><mixed-citation publication-type="journal" id="cit1">
<string-name>
<surname>Mulholland</surname>
<given-names>K</given-names>
</string-name>. <article-title>Global burden of acute respiratory infections in children: implications for interventions</article-title>. <source>Pediatr Pulmonol</source>
<year>2003</year>; <volume>36</volume>:<fpage>469</fpage>&#x02013;<lpage>474</lpage>.<pub-id pub-id-type="pmid">14618637</pub-id></mixed-citation></ref><ref id="b2"><label>2</label><mixed-citation publication-type="journal" id="cit2">
<string-name>
<surname>Girard</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Cherian</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Pervikov</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kieny</surname>
<given-names>MP</given-names>
</string-name>. <article-title>A review of vaccine research and development: human acute respiratory infections</article-title>. <source>Vaccine</source>
<year>2005</year>; <volume>23</volume>:<fpage>5708</fpage>&#x02013;<lpage>5724</lpage>.<pub-id pub-id-type="pmid">16154667</pub-id></mixed-citation></ref><ref id="b3"><label>3</label><mixed-citation publication-type="journal" id="cit3">
<string-name>
<surname>Arden</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>McErlean</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Nissen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sloots</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Mackay</surname>
<given-names>I</given-names>
</string-name>. <article-title>Frequent detection of human rhinoviruses, paramyxoviruses, coronaviruses, and bocavirus during acute respiratory tract infections</article-title>. <source>J Med Virol</source>
<year>2006</year>; <volume>78</volume>:<fpage>1232</fpage>&#x02013;<lpage>1240</lpage>.<pub-id pub-id-type="pmid">16847968</pub-id></mixed-citation></ref><ref id="b4"><label>4</label><mixed-citation publication-type="journal" id="cit4">
<string-name>
<surname>Nicholson</surname>
<given-names>KG</given-names>
</string-name>, <string-name>
<surname>McNally</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Silverman</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Simons</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Stockton</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Zambon</surname>
<given-names>MC</given-names>
</string-name>. <article-title>Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children</article-title>. <source>Vaccine</source>
<year>2006</year>; <volume>24</volume>:<fpage>102</fpage>&#x02013;<lpage>108</lpage>.<pub-id pub-id-type="pmid">16310899</pub-id></mixed-citation></ref><ref id="b5"><label>5</label><mixed-citation publication-type="journal" id="cit5">
<string-name>
<surname>Newall</surname>
<given-names>AT</given-names>
</string-name>, <string-name>
<surname>Scuffham</surname>
<given-names>PA</given-names>
</string-name>. <article-title>Influenza&#x02010;related disease: the cost to the Australian healthcare system</article-title>. <source>Vaccine</source>
<year>2008</year>; <volume>26</volume>:<fpage>6818</fpage>&#x02013;<lpage>6823</lpage>.<pub-id pub-id-type="pmid">18940222</pub-id></mixed-citation></ref><ref id="b6"><label>6</label><mixed-citation publication-type="journal" id="cit6">
<string-name>
<surname>Fiore</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Uyeki</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>Broder</surname>
<given-names>K</given-names>
</string-name>
<italic> et&#x000a0;al. </italic>
<article-title>Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010</article-title>. <source>MMWR Recomm Rep</source>
<year>2010</year>; <volume>59</volume>:<fpage>1</fpage>&#x02013;<lpage>62</lpage>.</mixed-citation></ref><ref id="b7"><label>7</label><mixed-citation publication-type="journal" id="cit7">
<string-name>
<surname>Sebastian</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Skowronski</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Chong</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dhaliwal</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Brownstein</surname>
<given-names>JS</given-names>
</string-name>. <article-title>Age&#x02010;related trends in the timeliness and prediction of medical visits, hospitalizations and deaths due to pneumonia and influenza, British Columbia, Canada, 1998&#x02010;2004</article-title>. <source>Vaccine</source>
<year>2008</year>; <volume>26</volume>:<fpage>1397</fpage>&#x02013;<lpage>1403</lpage>.<pub-id pub-id-type="pmid">18280620</pub-id></mixed-citation></ref><ref id="b8"><label>8</label><mixed-citation publication-type="journal" id="cit8">
<string-name>
<surname>Skowronski</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Woolcott</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tweed</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Brunham</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Marra</surname>
<given-names>F</given-names>
</string-name>. <article-title>Potential cost&#x02010;effectiveness of annual influenza immunization for infants and toddlers: experience from Canada</article-title>. <source>Vaccine</source>
<year>2006</year>; <volume>24</volume>:<fpage>4222</fpage>&#x02013;<lpage>4232</lpage>.<pub-id pub-id-type="pmid">16423432</pub-id></mixed-citation></ref><ref id="b9"><label>9</label><mixed-citation publication-type="journal" id="cit9">
<string-name>
<surname>Caliendo</surname>
<given-names>AM</given-names>
</string-name>. <article-title>Multiplex PCR and emerging technologies for the detection of respiratory pathogens</article-title>. <source>Clin Infect Dis</source>
<year>2011</year>; <volume>52</volume>(<issue>Suppl 4</issue>):<fpage>S326</fpage>&#x02013;<lpage>S330</lpage>.<pub-id pub-id-type="pmid">21460291</pub-id></mixed-citation></ref><ref id="b10"><label>10</label><mixed-citation publication-type="journal" id="cit10">
<string-name>
<surname>Heikkinen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Jarvinen</surname>
<given-names>A</given-names>
</string-name>. <article-title>The common cold</article-title>. <source>Lancet</source>
<year>2003</year>; <volume>361</volume>:<fpage>51</fpage>&#x02013;<lpage>59</lpage>.<pub-id pub-id-type="pmid">12517470</pub-id></mixed-citation></ref><ref id="b11"><label>11</label><mixed-citation publication-type="journal" id="cit11">
<string-name>
<surname>Bermingham</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Henrickson</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hayden</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Zambon</surname>
<given-names>M</given-names>
</string-name>. <article-title>VII international symposium on respiratory viral infections</article-title>. <source>Antivir Ther</source>
<year>2007</year>
<volume>12</volume>(<issue>4 Pt B</issue>): <fpage>671</fpage>&#x02013;<lpage>693</lpage>.<pub-id pub-id-type="pmid">17944274</pub-id></mixed-citation></ref><ref id="b12"><label>12</label><mixed-citation publication-type="journal" id="cit12">
<string-name>
<surname>van den Hoogen</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>de Jong</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Groen</surname>
<given-names>J</given-names>
</string-name>
<italic> et&#x000a0;al. </italic>
<article-title>A newly discovered human pneumovirus isolated from young children with respiratory tract disease</article-title>. <source>Nat Med</source>
<year>2001</year>; <volume>7</volume>:<fpage>719</fpage>&#x02013;<lpage>724</lpage>.<pub-id pub-id-type="pmid">11385510</pub-id></mixed-citation></ref><ref id="b13"><label>13</label><mixed-citation publication-type="journal" id="cit13">
<string-name>
<surname>Ksiazek</surname>
<given-names>TG</given-names>
</string-name>, <string-name>
<surname>Erdman</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Goldsmith</surname>
<given-names>CS</given-names>
</string-name>
<italic> et&#x000a0;al. </italic>
<article-title>A novel coronavirus associated with severe acute respiratory syndrome</article-title>. <source>N Engl J Med</source>
<year>2003</year>; <volume>348</volume>:<fpage>1953</fpage>&#x02013;<lpage>1966</lpage>.<pub-id pub-id-type="pmid">12690092</pub-id></mixed-citation></ref><ref id="b14"><label>14</label><mixed-citation publication-type="journal" id="cit14">
<string-name>
<surname>van der Hoek</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Pyrc</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Jebbink</surname>
<given-names>MF</given-names>
</string-name>
<italic> et&#x000a0;al. </italic>
<article-title>Identification of a new human coronavirus</article-title>. <source>Nat Med</source>
<year>2004</year>; <volume>10</volume>:<fpage>368</fpage>&#x02013;<lpage>373</lpage>.<pub-id pub-id-type="pmid">15034574</pub-id></mixed-citation></ref><ref id="b15"><label>15</label><mixed-citation publication-type="journal" id="cit15">
<string-name>
<surname>Woo</surname>
<given-names>PCY</given-names>
</string-name>, <string-name>
<surname>Lau</surname>
<given-names>SKP</given-names>
</string-name>, <string-name>
<surname>Chu</surname>
<given-names>C</given-names>
</string-name>
<italic> et&#x000a0;al. </italic>
<article-title>Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia</article-title>. <source>J Virol</source>
<year>2005</year>; <volume>79</volume>:<fpage>884</fpage>&#x02013;<lpage>895</lpage>.<pub-id pub-id-type="pmid">15613317</pub-id></mixed-citation></ref><ref id="b16"><label>16</label><mixed-citation publication-type="journal" id="cit16">
<string-name>
<surname>Allander</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tammi</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Eriksson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bjerkner</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tiveljung&#x02010;Lindell</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Andersson</surname>
<given-names>B</given-names>
</string-name>. <article-title>Cloning of a human parvovirus by molecular screening of respiratory tract samples</article-title>. <source>Proc Natl Acad Sci U S A</source>
<year>2005</year>; <volume>102</volume>:<fpage>12891</fpage>&#x02013;<lpage>12896</lpage>.<pub-id pub-id-type="pmid">16118271</pub-id></mixed-citation></ref><ref id="b17"><label>17</label><mixed-citation publication-type="journal" id="cit17">
<string-name>
<surname>Allander</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Andreasson</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Gupta</surname>
<given-names>S</given-names>
</string-name>
<italic> et&#x000a0;al. </italic>
<article-title>Identification of a third human polyomavirus</article-title>. <source>J Virol</source>
<year>2007</year>; <volume>81</volume>:<fpage>4130</fpage>&#x02013;<lpage>4136</lpage>.<pub-id pub-id-type="pmid">17287263</pub-id></mixed-citation></ref><ref id="b18"><label>18</label><mixed-citation publication-type="journal" id="cit18">
<string-name>
<surname>Gaynor</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Nissen</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Whiley</surname>
<given-names>DM</given-names>
</string-name>
<italic> et&#x000a0;al. </italic>
<article-title>Identification of a novel polyomavirus from patients with acute respiratory tract infections</article-title>. <source>PLoS Pathog</source>
<year>2007</year>; <volume>3</volume>:<fpage>e64</fpage>.<pub-id pub-id-type="pmid">17480120</pub-id></mixed-citation></ref><ref id="b19"><label>19</label><mixed-citation publication-type="journal" id="cit19">
<string-name>
<surname>Lambert</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Allen</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Druce</surname>
<given-names>JD</given-names>
</string-name>
<italic> et&#x000a0;al. </italic>
<article-title>Community epidemiology of human metapneumovirus, human coronavirus NL63, and other respiratory viruses in healthy preschool&#x02010;aged children using parent&#x02010;collected specimens</article-title>. <source>Pediatrics</source>
<year>2007</year>; <volume>120</volume>:<fpage>e929</fpage>&#x02013;<lpage>e937</lpage>.<pub-id pub-id-type="pmid">17875651</pub-id></mixed-citation></ref><ref id="b20"><label>20</label><mixed-citation publication-type="book" id="cit20">
<collab collab-type="authors">National Health and Medical Research Council</collab>
. <article-title>The Australian Immunisation Handbook</article-title>, <edition>9 edn</edition>
<year>2008</year>: <publisher-name>Australian Government Department of Health and Ageing</publisher-name>.</mixed-citation></ref><ref id="b21"><label>21</label><mixed-citation publication-type="book" id="cit21">
<collab collab-type="authors">Ministry of Health</collab>
, <article-title>Immunisation Handbook</article-title>. <year>2006</year>: <publisher-name>New Zealand Ministry of Health</publisher-name>.</mixed-citation></ref><ref id="b22"><label>22</label><mixed-citation publication-type="journal" id="cit22">
<string-name>
<surname>Lambert</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Whiley</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>O&#x02019;Neill</surname>
<given-names>NT</given-names>
</string-name>
<italic> et&#x000a0;al. </italic>
<article-title>Comparing nose&#x02010;throat swabs and nasopharyngeal aspirates collected from children with symptoms for respiratory virus identification using real&#x02010;time polymerase chain reaction</article-title>. <source>Pediatrics</source>
<year>2008</year>; <volume>122</volume>:<fpage>e615</fpage>&#x02013;<lpage>e620</lpage>.<pub-id pub-id-type="pmid">18725388</pub-id></mixed-citation></ref><ref id="b23"><label>23</label><mixed-citation publication-type="journal" id="cit23">
<string-name>
<surname>Lu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Holloway</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Dare</surname>
<given-names>RK</given-names>
</string-name>
<italic> et&#x000a0;al. </italic>
<article-title>Real&#x02010;time reverse transcription&#x02010;PCR assay for comprehensive detection of human rhinoviruses</article-title>. <source>J Clin Microbiol</source>
<year>2008</year>; <volume>46</volume>:<fpage>533</fpage>&#x02013;<lpage>539</lpage>.<pub-id pub-id-type="pmid">18057136</pub-id></mixed-citation></ref><ref id="b24"><label>24</label><mixed-citation publication-type="journal" id="cit24">
<string-name>
<surname>Arden</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Mackay</surname>
<given-names>IM</given-names>
</string-name>. <article-title>Newly identified human rhinoviruses: molecular methods heat up the cold viruses</article-title>. <source>Rev Med Virol</source>
<year>2010</year>; <volume>20</volume>:<fpage>156</fpage>&#x02013;<lpage>176</lpage>.<pub-id pub-id-type="pmid">20127751</pub-id></mixed-citation></ref><ref id="b25"><label>25</label><mixed-citation publication-type="journal" id="cit25">
<string-name>
<surname>Tozer</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Lambert</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Whiley</surname>
<given-names>DM</given-names>
</string-name>
<italic> et&#x000a0;al. </italic>
<article-title>Detection of human bocavirus in respiratory, fecal, and blood samples by real&#x02010;time PCR</article-title>. <source>J Med Virol</source>
<year>2009</year>; <volume>81</volume>:<fpage>488</fpage>&#x02013;<lpage>493</lpage>.<pub-id pub-id-type="pmid">19152414</pub-id></mixed-citation></ref><ref id="b26"><label>26</label><mixed-citation publication-type="journal" id="cit26">
<string-name>
<surname>Gunson</surname>
<given-names>RN</given-names>
</string-name>, <string-name>
<surname>Collins</surname>
<given-names>TC</given-names>
</string-name>, <string-name>
<surname>Carman</surname>
<given-names>WF</given-names>
</string-name>. <article-title>Real&#x02010;time RT&#x02010;PCR detection of 12 respiratory viral infections in four triplex reactions</article-title>. <source>J Clin Virol</source>
<year>2005</year>; <volume>33</volume>:<fpage>341</fpage>&#x02013;<lpage>344</lpage>.<pub-id pub-id-type="pmid">15927526</pub-id></mixed-citation></ref><ref id="b27"><label>27</label><mixed-citation publication-type="journal" id="cit27">
<string-name>
<surname>Dare</surname>
<given-names>RK</given-names>
</string-name>, <string-name>
<surname>Fry</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Chittaganpitch</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sawanpanyalert</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Olsen</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Erdman</surname>
<given-names>DD</given-names>
</string-name>. <article-title>Human coronavirus infections in rural Thailand: a comprehensive study using real&#x02010;time reverse&#x02010;transcription polymerase chain reaction assays</article-title>. <source>J Infect Dis</source>
<year>2007</year>; <volume>196</volume>:<fpage>1321</fpage>&#x02013;<lpage>1328</lpage>.<pub-id pub-id-type="pmid">17922396</pub-id></mixed-citation></ref><ref id="b28"><label>28</label><mixed-citation publication-type="journal" id="cit28">
<string-name>
<surname>Bialasiewicz</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Whiley</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Lambert</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Gould</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nissen</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Sloots</surname>
<given-names>TP</given-names>
</string-name>. <article-title>Development and evaluation of real&#x02010;time PCR assays for the detection of the newly identified KI and WU polyomaviruses</article-title>. <source>J Clin Virol</source>
<year>2007</year>; <volume>40</volume>:<fpage>9</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">17714984</pub-id></mixed-citation></ref><ref id="b29"><label>29</label><mixed-citation publication-type="journal" id="cit29">
<string-name>
<surname>Hayden</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Belshe</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Villanueva</surname>
<given-names>C</given-names>
</string-name>
<italic> et&#x000a0;al. </italic>
<article-title>Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis</article-title>. <source>J Infect Dis</source>
<year>2004</year>; <volume>189</volume>:<fpage>440</fpage>&#x02013;<lpage>449</lpage>.<pub-id pub-id-type="pmid">14745701</pub-id></mixed-citation></ref><ref id="b30"><label>30</label><mixed-citation publication-type="journal" id="cit30">
<string-name>
<surname>Kaczmarek</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Owen</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Barr</surname>
<given-names>IG</given-names>
</string-name>. <article-title>Annual report of the national influenza surveillance scheme, 2008</article-title>. <source>Commun Dis Intell</source>
<year>2010</year>; <volume>34</volume>:<fpage>8</fpage>&#x02013;<lpage>22</lpage>.</mixed-citation></ref><ref id="b31"><label>31</label><mixed-citation publication-type="journal" id="cit31">
<string-name>
<surname>Lambert</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Allen</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Carter</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Nolan</surname>
<given-names>TM</given-names>
</string-name>. <article-title>The cost of community&#x02010;managed viral respiratory illnesses in a cohort of healthy preschool&#x02010;aged children</article-title>. <source>Respir Res</source>
<year>2008</year>; <volume>9</volume>:<fpage>11</fpage>.<pub-id pub-id-type="pmid">18215329</pub-id></mixed-citation></ref><ref id="b32"><label>32</label><mixed-citation publication-type="journal" id="cit32">
<string-name>
<surname>Aanestad</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Nordbo</surname>
<given-names>SA</given-names>
</string-name>. <article-title>Virus interference. Did rhinoviruses activity hamper the progress of the 2009 influenza A (H1N1) pandemic in Norway?</article-title>
<source>Med Hypotheses</source>
<year>2011</year>; <volume>77</volume>:<fpage>1132</fpage>&#x02013;<lpage>1134</lpage>.<pub-id pub-id-type="pmid">21975051</pub-id></mixed-citation></ref><ref id="b33"><label>33</label><mixed-citation publication-type="journal" id="cit33">
<string-name>
<surname>Nichol</surname>
<given-names>KL</given-names>
</string-name>. <article-title>Heterogeneity of influenza case definitions and implications for interpreting and comparing study results</article-title>. <source>Vaccine</source>
<year>2006</year>; <volume>46</volume>:<fpage>6726</fpage>&#x02013;<lpage>6728</lpage>.</mixed-citation></ref><ref id="b34"><label>34</label><mixed-citation publication-type="journal" id="cit34">
<string-name>
<surname>Mohan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Chandra</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Agarwal</surname>
<given-names>D</given-names>
</string-name>
<italic> et&#x000a0;al. </italic>
<article-title>Prevalence of viral infection detected by PCR and RT&#x02010;PCR in patients with acute exacerbation of COPD: a systematic review</article-title>. <source>Respirology</source>
<year>2010</year>; <volume>15</volume>:<fpage>536</fpage>&#x02013;<lpage>542</lpage>.<pub-id pub-id-type="pmid">20415983</pub-id></mixed-citation></ref><ref id="b35"><label>35</label><mixed-citation publication-type="journal" id="cit35">
<string-name>
<surname>Grant</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Carville</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Fielding</surname>
<given-names>JE</given-names>
</string-name>
<italic> et&#x000a0;al. </italic>
<article-title>High proportion of influenza B characterises the 2008 influenza season in Victoria</article-title>. <source>Commun Dis Intell</source>
<year>2009</year>; <volume>33</volume>:<fpage>328</fpage>&#x02013;<lpage>336</lpage>.</mixed-citation></ref><ref id="b36"><label>36</label><mixed-citation publication-type="journal" id="cit36">
<string-name>
<surname>Hutchinson</surname>
<given-names>AF</given-names>
</string-name>, <string-name>
<surname>Ghimire</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>MA</given-names>
</string-name>
<italic> et&#x000a0;al. </italic>
<article-title>A community&#x02010;based, time&#x02010;matched, case&#x02010;control study of respiratory viruses and exacerbations of COPD</article-title>. <source>Respir Med</source>
<year>2007</year>; <volume>101</volume>:<fpage>2472</fpage>&#x02013;<lpage>2481</lpage>.<pub-id pub-id-type="pmid">17822891</pub-id></mixed-citation></ref><ref id="b37"><label>37</label><mixed-citation publication-type="journal" id="cit37">
<string-name>
<surname>Rohde</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Wiethege</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Borg</surname>
<given-names>I</given-names>
</string-name>
<italic> et&#x000a0;al. </italic>
<article-title>Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case&#x02010;control study</article-title>. <source>Thorax</source>
<year>2003</year>; <volume>58</volume>:<fpage>37</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">12511718</pub-id></mixed-citation></ref><ref id="b38"><label>38</label><mixed-citation publication-type="journal" id="cit38">
<string-name>
<surname>McManus</surname>
<given-names>TE</given-names>
</string-name>, <string-name>
<surname>Marley</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Baxter</surname>
<given-names>N</given-names>
</string-name>
<italic> et&#x000a0;al. </italic>
<article-title>Respiratory viral infection in exacerbations of COPD</article-title>. <source>Respir Med</source>
<year>2008</year>; <volume>102</volume>:<fpage>1575</fpage>&#x02013;<lpage>1580</lpage>.<pub-id pub-id-type="pmid">18672353</pub-id></mixed-citation></ref><ref id="b39"><label>39</label><mixed-citation publication-type="journal" id="cit39">
<string-name>
<surname>Ko</surname>
<given-names>FWS</given-names>
</string-name>, <string-name>
<surname>Ip</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>PKS</given-names>
</string-name>
<italic> et&#x000a0;al. </italic>
<article-title>Viral etiology of acute exacerbations of COPD in Hong Kong</article-title>. <source>Chest</source>
<year>2007</year>; <volume>132</volume>:<fpage>900</fpage>&#x02013;<lpage>908</lpage>.<pub-id pub-id-type="pmid">17573516</pub-id></mixed-citation></ref><ref id="b40"><label>40</label><mixed-citation publication-type="journal" id="cit40">
<string-name>
<surname>Lambert</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>O&#x02019;Grady</surname>
<given-names>KF</given-names>
</string-name>, <string-name>
<surname>Gabriel</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Nolan</surname>
<given-names>TM</given-names>
</string-name>. <article-title>Respiratory illness during winter: a cohort study of urban children from temperate Australia</article-title>. <source>J Paediatr Child Health</source>
<year>2005</year>; <volume>41</volume>:<fpage>125</fpage>&#x02013;<lpage>129</lpage>.<pub-id pub-id-type="pmid">15790323</pub-id></mixed-citation></ref><ref id="b41"><label>41</label><mixed-citation publication-type="journal" id="cit41">
<string-name>
<surname>Isaacs</surname>
<given-names>D</given-names>
</string-name>. <article-title>Should all Australian children be vaccinated against influenza?</article-title>
<source>Med J Aust</source>
<year>2005</year>; <volume>182</volume>:<fpage>553</fpage>&#x02013;<lpage>554</lpage>.<pub-id pub-id-type="pmid">15938679</pub-id></mixed-citation></ref><ref id="b42"><label>42</label><mixed-citation publication-type="journal" id="cit42">
<string-name>
<surname>Mogasale</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Barendregt</surname>
<given-names>J</given-names>
</string-name>. <article-title>Cost&#x02010;effectiveness of influenza vaccination of people aged 50&#x02010;64&#x02003;years in Australia: results are inconclusive</article-title>. <source>Aust N Z J Public Health</source>
<year>2011</year>; <volume>35</volume>:<fpage>180</fpage>&#x02013;<lpage>186</lpage>.<pub-id pub-id-type="pmid">21463417</pub-id></mixed-citation></ref></ref-list></back></article>